Sherlock Biosciences Unveils State-of-the-Art UK Biomanufacturing Facility
Cambridge-based manufacturing facility will support production of 5 million diagnostic devices, with capacity to grow, as the company approaches commercialization
CAMBRIDGE, UK and WATERTOWN, MA, August 15, 2023 — Sherlock Biosciences, a company engineering biology to bring next-generation diagnostics over-the-counter and beyond, today announced the launch of its new biomanufacturing facilities, located outside of Cambridge, UK. The state-of-the-art 36,000 square foot manufacturing facility will expand Sherlock’s global diagnostic capacity in the lead-up to commercialization.
“The opening of this new facility is the latest milestone following Sherlock’s acquisition of Sense Biodetection earlier this year,” said Bryan Dechairo, CEO of Sherlock. “Since then, while preparing the biomanufacturing center, we’ve been melding our teams together, as well as integrating chemistry, manufacturing capabilities and technology. We’re excited to enter this next phase together and are poised to change the course of global health.”
The campus includes a purpose-built, ISO 13485-certified 36,000 square foot manufacturing facility, featuring Class 8 clean rooms where Sherlock is currently validating production capabilities for proprietary disposable molecular diagnostic devices, lyophilized reagent beads and carbon particle lateral flow strips. The facility enables Sherlock to rapidly and flexibly scale low-cost manufacturing of its affordable, accurate and accessible molecular diagnostics across several years of commercial growth.
“We built this facility with a pragmatic approach to scale-up, ensuring we had capacity for what the company needs at each stage of its growth,” said Kristin Riley Sherlock’s VP, Operations. “Central to our design was our commitment to ensuring that we deliver affordable diagnostics to the world, and because of the scale and infrastructure of this facility we can deliver on this commitment today and in the future.”
About Sherlock Biosciences
Sherlock Biosciences is a global health company that is bringing diagnostics answers over the counter and beyond. Sherlock’s molecular diagnostics leverage proprietary CRISPR and SynBio chemistries to rapidly deliver results anytime, anywhere they are needed, bringing together the lab accuracy of PCR with the convenience and ease-of-use of antigen tests for molecular diagnostics at the point-of-need. Two novel device platforms including a disposable format, deliver affordable, accurate and accessible diagnostics in the home and in low resource settings, opening up a wide range of applications in areas including infectious disease, early detection of cancer, treatment monitoring and precision medicine. In 2020, the company made history with the first FDA-authorized use of CRISPR technology. For more information, please visit www.sherlock.bio.
Contact
sherlockbio@consortpartners.com